Mochi Health Pricing History and Trajectory: What You Should Know Before You Subscribe

What Mochi Health Actually Is

Mochi Health is a telehealth weight-management company that connects patients with licensed clinicians to prescribe GLP-1 receptor agonists such as semaglutide and tirzepatide. The company operates on a subscription model that combines a recurring membership fee with separately billed medication costs, and it optionally submits claims to commercial insurance plans.

The company is not a pharmacy. Prescriptions are routed to compounding pharmacies or retail pharmacies depending on the patient's coverage and the specific drug ordered. That distinction matters for cost, because compounded semaglutide from a 503A or 503B pharmacy is priced very differently from brand-name Wegovy or Ozempic filled at a retail chain.

The GLP-1 Market Context

GLP-1 receptor agonists have strong clinical evidence behind them. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% on placebo (P<0.001) [1]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% on placebo [2]. Those results drive enormous consumer demand, which in turn created the commercial environment in which Mochi Health, and a dozen competitors, built subscription-based prescribing platforms.

How Telehealth Pricing Stacks Up

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that "access, affordability, and adherence support are determinants of long-term treatment success" [3]. That framing is relevant here because pricing trajectory directly affects whether patients stay on therapy long enough to achieve the weight loss outcomes seen in clinical trials.

Mochi Health Pricing: A Year-by-Year Reconstruction

Exact historical pricing is difficult to verify independently because Mochi Health, like most telehealth startups, has changed its pricing page multiple times without publishing a formal changelog. The reconstruction below draws on archived web pages, consumer complaint timestamps, and independent journalist reporting.

2022: Early Cash-Pay Launch Pricing

When Mochi Health began scaling in 2022, its primary offer was a single membership tier priced near $99/month. At that price point, members received access to a clinician visit, ongoing messaging, and a care team. Medication costs were separate and varied based on which pharmacy fulfilled the prescription.

Compounded semaglutide was becoming widely available from 503A pharmacies during this period because the FDA had placed semaglutide on its drug-shortage list, a designation that legally permitted compounding [4]. That shortage listing kept compounded drug costs lower than they would otherwise be, with prices typically ranging from $150 to $250/month for lower starting doses.

2023: Tiered Plans and Insurance Integration

Through 2023, Mochi Health expanded its plan structure. Membership tiers began to differentiate between patients who wanted insurance billing support and those paying entirely out of pocket. A higher tier, reported by multiple users in archived reviews and complaint filings, climbed toward $149, $199/month for the membership component alone.

Insurance billing was rolled out more broadly. Patients with commercial insurance who qualified for Wegovy (FDA-approved for BMI >30, or BMI >27 with a weight-related comorbidity) could potentially have the drug covered under their pharmacy benefit [5]. For those patients, the out-of-pocket cost of the membership fee was the dominant expense.

For cash-pay patients, the total cost rose because doses were being titrated upward and per-unit costs scaled with dose.

2024: Regulatory Pressure and Pricing Shifts

The FDA began signaling in late 2023 and into 2024 that it would revisit the semaglutide shortage designation. In October 2024, the FDA removed semaglutide from the official shortage list, which placed compounding pharmacies in a legally precarious position [6]. Mochi Health, like other platforms relying on compounded semaglutide, had to communicate that regulatory risk to patients.

During this period, some patients reported receiving notices that their medication source or pricing would change. The shift pushed some users toward branded drugs through insurance, which required meeting prior authorization criteria, or toward compounded tirzepatide, which remained on a shortage designation longer.

Membership pricing during 2024 was reported by consumers in the range of $99, $199/month for the subscription, with compounded semaglutide in the $200, $350/month range and compounded tirzepatide reaching $399/month or above at higher doses.

2025: Current Reported Pricing

As of mid-2025, Mochi Health's publicly visible pricing places the standard membership at approximately $99/month. The company also advertises an "all-inclusive" plan structure in some markets, but independent verification of exactly what is bundled versus separately billed remains difficult because the pricing page changes periodically.

The FDA's enforcement posture toward 503A compounders dispensing copies of commercially available semaglutide products has tightened, with the agency issuing guidance that nominates such dispensing as potentially violating the Federal Food, Drug, and Cosmetic Act [7]. That creates forward pricing uncertainty for any platform, including Mochi Health, that relies on compounded semaglutide volume.

HealthRX Total Cost Framework for Mochi Health (mid-2025 estimates):

| Scenario | Membership/Month | Medication/Month | Estimated Total/Month | |---|---|---|---| | Cash-pay, compounded semaglutide (low dose) | $99 | $149, $199 | $248, $298 | | Cash-pay, compounded semaglutide (maintenance dose) | $99, $149 | $249, $349 | $348, $498 | | Cash-pay, compounded tirzepatide | $99, $149 | $299, $449 | $398, $598 | | Insurance billing, branded GLP-1 covered | $99, $149 | Copay varies ($0, $150) | $99, $299+ | | Insurance billing, branded GLP-1 denied | $99, $149 | Full retail ($800, $1,300+) | Prohibitive without coupon |

These figures are reconstructions based on publicly reported pricing and consumer reviews, not direct billing data from Mochi Health.

Is Mochi Health Legit?

The short answer is yes, with qualifications. Mochi Health operates with licensed clinicians, uses real pharmacies, and prescribes FDA-approved drug classes. But "legit" and "right for every patient" are different questions.

Licensing and Clinical Operations

Mochi Health employs or contracts with licensed physicians and nurse practitioners. Prescriptions are written within the scope of practice defined by each state's medical board. Compounded medications, when dispensed, come from pharmacies that are required to be licensed at the state level and, for 503B facilities, registered with the FDA [8].

The FDA does not endorse or certify telehealth platforms as a category. LegitScript, a certification service used by some online pharmacies and telehealth companies, lists compliance status for pharmacy partners but does not certify telehealth prescribing platforms directly. Patients should verify that any pharmacy Mochi Health routes their prescription to holds a current state pharmacy license in the patient's state of residence.

BBB Record and Consumer Complaints

Mochi Health is not accredited by the Better Business Bureau as of mid-2025. The BBB profile for Mochi Health shows a pattern of complaints, with the most common themes being:

• Billing charges continuing after a patient believed they had cancelled
• Difficulty reaching customer support to resolve billing disputes
• Delays between membership start and first clinical appointment
• Prescription delays due to pharmacy coordination issues

These complaint types are not unique to Mochi Health. They appear across most subscription-based telehealth platforms in the GLP-1 space. Still, the volume and recurrence of billing-related complaints is worth noting before entering a subscription.

The Federal Trade Commission has published guidance on negative-option marketing (subscriptions that auto-renew unless actively cancelled), and the FTC's "Click to Cancel" rule, finalized in 2024, creates new disclosure requirements for companies like Mochi Health that use recurring billing [9].

Clinical Legitimacy Versus Commercial Concerns

Mochi Health's prescribing practices appear consistent with obesity medicine guidelines. The American Academy of Family Physicians and the Obesity Medicine Association both support pharmacotherapy for patients with a BMI >30, or BMI >27 with comorbidities, when lifestyle interventions alone are insufficient [10]. Mochi Health's intake process reportedly includes BMI screening and medical history review, which aligns with standard prescribing criteria.

The clinical concern is not whether the drugs work. It is whether the platform provides adequate long-term follow-up, side-effect monitoring, and dose adjustment, which are functions that are sometimes compressed in high-volume telehealth operations.

Mochi Health Complaints: Patterns and What They Reveal

A systematic look at consumer complaints filed with the BBB, Trustpilot, Reddit, and state attorney general offices (where accessible) reveals several recurring issues.

Billing and Cancellation

The most common complaint category involves billing after cancellation. Patients report submitting cancellation requests through the app or website and then being charged for one or more additional billing cycles. Some report difficulty locating a cancellation mechanism without contacting customer support directly.

Under the FTC's updated Negative Option Rule, companies are required to provide a simple cancellation mechanism that is at least as easy as the sign-up process [9]. Whether Mochi Health's current cancellation flow meets that standard is a factual question that individual patients should evaluate at sign-up.

Prescription and Fulfillment Delays

A second complaint pattern involves delays between membership activation and receiving the first prescription or medication shipment. Some patients report waiting two to four weeks for an initial appointment, then additional time for the pharmacy to fulfill the compounded medication. For patients who have already paid a monthly membership fee, this dead time is a direct cost with no clinical benefit.

Medication Continuity Under Regulatory Change

The FDA's actions on compounded semaglutide created a third complaint pattern in 2024 and into 2025. Some patients report being notified that their compounded medication would no longer be available through their current pharmacy, then experiencing a gap in therapy while Mochi Health arranged an alternative source. Gaps in GLP-1 therapy can lead to rebound weight gain, as the pharmacological appetite suppression effect reverses within weeks of discontinuation [11].

Positive Reviews and Counterbalancing Reports

Not all reports are negative. A meaningful share of reviews across platforms describe successful weight loss, responsive prescribers, and efficient insurance handling. The distribution of outcomes appears genuinely bimodal: patients who manage the onboarding and billing systems smoothly report positive experiences, while patients who encounter friction at the billing or pharmacy coordination layer report frustration.

GLP-1 Pricing Across the Telehealth Sector

Mochi Health does not set prices in isolation. Its pricing sits within a competitive telehealth market that includes Hims and Hers Health, Ro, Found, WeightWatchers Clinic, and others. Each uses a variation of the membership-plus-medication model.

Branded Wegovy (semaglutide 2.4 mg) had a list price of approximately $1,349/month as of early 2025 before manufacturer savings cards or insurance. Novo Nordisk's savings card for commercially insured patients can reduce that to $0, $25/month for eligible individuals, but patients without qualifying insurance receive no benefit [12].

Compounded semaglutide from 503B outsourcing facilities can be priced between $150 and $400/month depending on dose and supplier, making telehealth platforms with compounding relationships a meaningful cost reduction for uninsured or underinsured patients, provided the regulatory environment permits continued compounding access.

The CDC reports that 41.9% of U.S. Adults have obesity (BMI >30), and a large fraction of those individuals do not have insurance coverage that includes anti-obesity medications [13]. That access gap is the structural driver behind the entire telehealth GLP-1 market, including Mochi Health's pricing strategy.

What the Pricing Trajectory Suggests About Future Costs

Three forces are likely to shape Mochi Health's pricing over the next 12 to 24 months.

FDA Compounding Enforcement

If the FDA follows through on its enforcement discretion deadline for 503A compounders dispensing copies of semaglutide, platforms that have built their cash-pay model on compounded semaglutide will face either a drug supply disruption or a forced pivot to tirzepatide (which remains on shortage for longer) or to branded drugs through insurance. Either path likely increases costs for patients who currently pay cash-pay compounded prices.

Biosimilar Entry

Semaglutide biosimilars are in development. The first FDA-approved semaglutide biosimilar for weight management could enter the market as early as 2026 to 2028 once applicable exclusivity periods expire. Biosimilar entry historically reduces branded drug prices by 30%, 80% within 24 months of launch, based on the insulin biosimilar experience [14]. If that pattern holds, cash-pay patients on platforms like Mochi Health could see lower medication costs in the medium term.

Insurance Coverage Expansion

The Centers for Medicare and Medicaid Services has proposed extending GLP-1 coverage to Medicare Part D beneficiaries with obesity but without diabetes. If that rule is finalized, more Mochi Health patients may shift to insurance billing, changing the revenue mix and potentially the membership fee structure for cash-pay patients who subsidize the insurance-navigation infrastructure.

How to Evaluate Mochi Health Before Subscribing

Patients considering Mochi Health should take five concrete steps before entering a subscription.

First, confirm that the prescribing clinician assigned to your care is licensed in your state. State medical board license lookup tools are free and publicly accessible.

Second, ask specifically which pharmacy will fulfill your prescription, then verify that pharmacy holds a current license in your state. For compounded medications, ask whether the pharmacy is a 503A or 503B facility and whether it has an FDA inspection record.

Third, read the cancellation policy before payment, not after. Specifically locate the mechanism for cancelling recurrent billing and document it.

Fourth, ask whether your medication cost is guaranteed for a defined period or subject to change. Get the answer in writing through the platform's secure messaging system.

Fifth, if insurance billing is part of your plan, ask Mochi Health's care team what happens to your prescription if prior authorization is denied. Understanding the fallback path before denial saves weeks of disruption.